Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Mechanisms of Azacitidine Chemotherapy Resistance in AML and MDS and New Therapy Options

Lubomir Minarik, MD, Leylah M. Drusbosky, PhD, Taher Abbasi, MS, MBA, Karina Vargova, MBBS, MSc, Vojtech Kulvait, PhD, Anna Jonasova, MD, Neeraj Kumar Singh, B.Tech, Chandan Kumar, M.Tech, Rakhi Purushothaman Suseela, B.Tech, Mamatha Patil, B.E, Patil Nilesh Dattatraya, M.Sc., Krishna Kumar Tiwari, B.Tech, Shireen Vali, PhD, Christopher R. Cogle, MD, Tomas Stopka, MD PhD

Blood (2018) 132 (Supplement 1): 5506.

https://doi.org/10.1182/blood-2018-99-114466

Published: 2018

Journal Articles

Predicting Carfilzomib Resistance Mechanisms and Therapeutics Using Computational Modelling of Genomics and Proteomics

Andrej Besse, M.Sc, Christopher R. Cogle, MD, Leylah M. Drusbosky, PhD, Shireen Vali, PhD, Taher Abbasi, MS, MBA, Neeraj Kumar Singh, B.Tech, Neha G Gupta, M.Sc., Abha Kushwaha, M.Sc., Pallavi Kumari, M.Sc., Karthik Sundara Raju, M.Sc., Ganesh Naga, B.Tech, Sayani Basu, M.Tech, Christoph Driessen, MD, Lenka Besse, PhD

Blood (2018) 132 (Supplement 1): 3193.

https://doi.org/10.1182/blood-2018-99-116939

Published: 2018

Journal Articles

Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor–refractory multiple myeloma

Christoph Driessen, Rouven Müller, Urban Novak, Nathan Cantoni, Daniel Betticher, Nicolas Mach, Axel Rüfer, Ulrich Mey, Panagiotis Samaras, Karin Ribi, Lenka Besse, Andrej Besse, Catherine Berset, Stephanie Rondeau, Hanne Hawle, Felicitas Hitz, Thomas Pabst, Thilo Zander

Blood (2018) 132 (19): 2097–2100.

https://doi.org/10.1182/blood-2018-05-851170

Published: 2018

Includes: Supplemental data

Journal Articles

Nelfinavir and Lenalidomide/Dexamethasone in Patients with Lenalidomide-Refractory Multiple Myeloma. A Phase I/II Trial — SAKK 39/10

Felicitas - Hitz, MD, Thomas - Pabst, MD, Dagmar - Hess, MD, Marianne Kraus, Lenka Besse, Urban Novak, MD, Katja - Seipel, MD, Stephanie - Rondeau, Silvia - Stüdeli, Simona Berardi, MD, Samaras Panagiotis, MD, Ulrich Mey, MD, Christoph Driessen, MD

Blood (2017) 130 (Supplement 1): 1884.

https://doi.org/10.1182/blood.V130.Suppl_1.1884.1884

Published: 2017

Journal Articles

Predictive Simulation Modeling of Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Patient Genomics Identifies Targeted Combination Treatment Options

Leylah M. Drusbosky, PhD, Ansu Kumar, MS, Shwetha K, BE, Priyanka Bhargav, BE, Ashish Choudhary, MS, Soumyashree L, BE, Shivgonda C. Birajdar, MCA, Kunal Ghosh Roy, MS, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Manju Sengar, MD DM, Girish Chinnaswamy, MD MRCP, Bijal D. Shah, MD, Christopher R. Cogle, MD

Blood (2017) 130 (Supplement 1): 2708.

https://doi.org/10.1182/blood.V130.Suppl_1.2708.2708

Published: 2017

Journal Articles

Nelfinavir Blocks Export of Newly Synthesized Protein from the ER and Interacts with ER-Resident and Mitochondrial Proteins in an Activity-Dependent Fashion

Andrej Besse, Lenka Besse, Sara C. Stolze, Marianne Kraus, Juergen Bader, Herman S Overkleeft, Christoph Driessen, MD

Blood (2017) 130 (Supplement 1): 3074.

https://doi.org/10.1182/blood.V130.Suppl_1.3074.3074

Published: 2017

Journal Articles

Personalized Therapy Design for Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Using Computational Biology Modeling with in Vitro Validation

Madeleine Turcotte, MS, Raphael Charles Bosse, BS, MD PhD, Kimberly E. Hawkins, PhD BS, Amy Meacham, MS, Vindhya Vijay, MS, Girish Chinnaswamy, MD MRCP, Manju Sengar, MD DM, Ansu Kumar, MS, Shwetha K, BE, Anisha Kamath, BT, Anjana T. Nair, MS, Karthik S. Raju, MS, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Christopher R. Cogle, MD, Leylah M. Drusbosky, PhD

Blood (2017) 130 (Supplement 1): 1448.

https://doi.org/10.1182/blood.V130.Suppl_1.1448.1448

Published: 2017

Journal Articles

The HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib and Dexamethasone (NVd) Has Excellent Activity in Patients with Advanced, Proteasome Inhibitor-Refractory Multiple Myeloma: A Multicenter Phase II Trial (SAKK 39/13)

Christoph Driessen, MD PhD, Rouven Müller, MD, Urban Novak, MD, Nathan Cantoni, MD, Daniel Betticher, Nicolas Mach, Michael Gregor, Panagiotis Samaras, MD, Catherine Berset, Stephanie Rondeau, Hanne Hawle, MD, Felicitas Hitz, MD, Thomas Pabst, MD PhD, Thilo Zander, MD

Blood (2016) 128 (22): 487.

https://doi.org/10.1182/blood.V128.22.487.487

Published: 2016

Journal Articles

SAKK 65/08: A Phase I Dose Escalation Study of Bortezomib in Combination with Nelfinavir in Patients with Advanced Hematologic Malignancies

Christoph Driessen, MD, Jürgen Bader, Marianne Kraus, PhD, Markus Jörger, MD PhD, Hilde Rosing, PhD, Gregoire Berthod, MD, Felicitas Hitz, MD, Catherine Berset, PhD, Alexandros Xyrafas, Hanne Hawle, MD, Hermann S Overkleeft, PhD, Christiana Sessa, MD, Alwin Huitema, PhD, Ulrich JM Mey, Thomas Pabst, MD, Roger von Moos, MD, Dagmar Hess, MD

Blood (2014) 124 (21): 4747.

https://doi.org/10.1182/blood.V124.21.4747.4747

Published: 2014

Journal Articles

Epidemiology and Outcomes of Respiratory Virus Infections in Adult Acute Leukemia and Hematopoietic Stem Cell Transplant Patients

Gaurav Trikha, MBBS, MD, Rebecca Conway, BSN, John W Hiemenz, MD, Per T. Ljungman, MD PhD

Blood (2014) 124 (21): 4984.

https://doi.org/10.1182/blood.V124.21.4984.4984

Published: 2014

Journal Articles

A Novel Simulation Method for Mapping Dysregulated Pathways and Predicting Effective Therapeutics in the Myelodysplastic Syndromes

Christopher R. Cogle, MD, Kaoru Tohyama, MD PhD, Shireen Vali, PhD, Ansu Kumar, Neeraj Kumar Singh, Krishna Kumar Tiwari, Anuj Tyagi, Taher Abbasi, MS, Peter P. Sayeski, PhD

Blood (2014) 124 (21): 5595.

https://doi.org/10.1182/blood.V124.21.5595.5595

Published: 2014

Journal Articles

A Novel Method of Using Molecular Profiling in Myelodysplastic Syndromes to Predict Patient-Specific Potential Therapeutics

Christopher R. Cogle, MD, Gaurav Trikha, MBBS, MD, Peter P. Sayeski, PhD, Shireen Vali, PhD, Ansu Kumar, Neeraj Kumar Singh, Prashant R Nair, Deepak Anil Lala, Kabya Basu, Taher Abbasi, MS, Maher Albitar, MD

Blood (2014) 124 (21): 5591.

https://doi.org/10.1182/blood.V124.21.5591.5591

Published: 2014

Journal Articles

Identification of Endoplasmic Reticulum Stress Inducing Agents by Antagonizing Autophagy: A New Potential Strategy for Identification of Anti-Cancer Therapeutics in B-Cell Malignancies.

Emilia Mahoney, MD, PhD, Sara L Cole, PhD, Kami Maddocks, MD, Joseph M. Flynn, DO, MPH, Jeffrey A. Jones, MD, MPH, Xiaoli Zhang, PhD, MS, John C. Byrd, MD, Amy J. Johnson, PhD

Blood (2012) 120 (21): 2473.

https://doi.org/10.1182/blood.V120.21.2473.2473

Published: 2012

Journal Articles

SAKK 65/08: A Phase I Trial of the HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib Identifies Nelfinavir As FDA Approved, Oral Drug that Inhibits the Proteasome and Induces Proteotoxic Stress in Vivo and has Potential Antimyeloma Activity.

Christoph Driessen, MD, Dagmar Hess, MD, Thomas Pabst, MD, Sarah R Haile, Markus Joerger, MD, Roger von Moos, MD, Catherine Berset, Susanne Crowe, Hilde Rosing, PhD, Hermen S Overkleeft, Christiana Sessa, Marianne Kraus

Blood (2012) 120 (21): 2956.

https://doi.org/10.1182/blood.V120.21.2956.2956

Published: 2012

Journal Articles

Nelfinavir Activates Epstein-Barr Virus and Kaposi's Sarcoma Herpesvirus Lytic Cycle by Inducing ER Stress

Courtney Shirley, BS, Nene Kalu, MS, Richard F Ambinder, MD, PhD

Blood (2011) 118 (21): 5011.

https://doi.org/10.1182/blood.V118.21.5011.5011

Published: 2011

Journal Articles

Genomic and Pathway Connectivity Analyses Identify Novel Strategies to Overcome mTOR Inhibitor Resistance In DLBCL

Adam M. Petrich, MD, Violetta V. Leshchenko, PhD, Pei-Yu Kuo, MS, B. Hilda Ye, PhD, Joseph A Sparano, MD, Samir Parekh, MD

Blood (2010) 116 (21): 436.

https://doi.org/10.1182/blood.V116.21.436.436

Published: 2010

Journal Articles

The HIV Protease Inhibitor Nelfinavir: A Unique Oral Drug That Inhibits the Proteasome and AKT-Phosphorylation, Induces ER Stress and Sensitizes Bortezomib-Refractory Primary Myeloma Cells and Primary AML Cells towards Bortezomib

Christoph Driessen, MD, Jürgen Bader, Marianne Kraus

Blood (2010) 116 (21): 4069.

https://doi.org/10.1182/blood.V116.21.4069.4069

Published: 2010

Journal Articles

Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid–based proteasome inhibitors

Encouse B. Golden, Philip Y. Lam, Adel Kardosh, Kevin J. Gaffney, Enrique Cadenas, Stan G. Louie, Nicos A. Petasis, Thomas C. Chen, Axel H. Schönthal

Blood (2009) 113 (23): 5927–5937.

https://doi.org/10.1182/blood-2008-07-171389

Published: 2009

Journal Articles

Inhibition of Autophagy Promotes Bortezomib-Mediated Cell Death in Myeloma Cells

Terry H. Landowski, PhD, Aluvia M Escalante, Andrew Jefferson, Robert T Dorr, Ronald Lynch

Blood (2008) 112 (11): 3677.

https://doi.org/10.1182/blood.V112.11.3677.3677

Published: 2008

NARROW

Mechanisms of Azacitidine Chemotherapy Resistance in AML and MDS and New Therapy Options

Predicting Carfilzomib Resistance Mechanisms and Therapeutics Using Computational Modelling of Genomics and Proteomics

Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor–refractory multiple myeloma

Nelfinavir and Lenalidomide/Dexamethasone in Patients with Lenalidomide-Refractory Multiple Myeloma. A Phase I/II Trial — SAKK 39/10

Predictive Simulation Modeling of Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Patient Genomics Identifies Targeted Combination Treatment Options

Nelfinavir Blocks Export of Newly Synthesized Protein from the ER and Interacts with ER-Resident and Mitochondrial Proteins in an Activity-Dependent Fashion

Personalized Therapy Design for Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Using Computational Biology Modeling with in Vitro Validation

The HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib and Dexamethasone (NVd) Has Excellent Activity in Patients with Advanced, Proteasome Inhibitor-Refractory Multiple Myeloma: A Multicenter Phase II Trial (SAKK 39/13)

SAKK 65/08: A Phase I Dose Escalation Study of Bortezomib in Combination with Nelfinavir in Patients with Advanced Hematologic Malignancies

Epidemiology and Outcomes of Respiratory Virus Infections in Adult Acute Leukemia and Hematopoietic Stem Cell Transplant Patients

A Novel Simulation Method for Mapping Dysregulated Pathways and Predicting Effective Therapeutics in the Myelodysplastic Syndromes

A Novel Method of Using Molecular Profiling in Myelodysplastic Syndromes to Predict Patient-Specific Potential Therapeutics

Identification of Endoplasmic Reticulum Stress Inducing Agents by Antagonizing Autophagy: A New Potential Strategy for Identification of Anti-Cancer Therapeutics in B-Cell Malignancies.

SAKK 65/08: A Phase I Trial of the HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib Identifies Nelfinavir As FDA Approved, Oral Drug that Inhibits the Proteasome and Induces Proteotoxic Stress in Vivo and has Potential Antimyeloma Activity.

Nelfinavir Activates Epstein-Barr Virus and Kaposi's Sarcoma Herpesvirus Lytic Cycle by Inducing ER Stress

Genomic and Pathway Connectivity Analyses Identify Novel Strategies to Overcome mTOR Inhibitor Resistance In DLBCL

The HIV Protease Inhibitor Nelfinavir: A Unique Oral Drug That Inhibits the Proteasome and AKT-Phosphorylation, Induces ER Stress and Sensitizes Bortezomib-Refractory Primary Myeloma Cells and Primary AML Cells towards Bortezomib

Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid–based proteasome inhibitors

Inhibition of Autophagy Promotes Bortezomib-Mediated Cell Death in Myeloma Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only